Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-beta treatment for multiple sclerosis.

Robert A Bermel1, Richard A Rudick

  • 1Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|October 9, 2007
PubMed
Summary
This summary is machine-generated.

Interferon-beta is a key treatment for multiple sclerosis (MS), reducing relapses and slowing disability. Research continues to explore its anti-inflammatory effects and optimize its use in MS patients.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationships between neighborhood deprivation, race, and worsening outcomes among MS patients 55 years of age and older.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Beyond the 2024 McDonald criteria for defining and diagnosing multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

Longitudinal modeling of upper extremity function in multiple sclerosis: Associations for clinical and sociodemographic factors.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

AI-driven reclassification of multiple sclerosis progression.

Nature medicine·2025
Same author

Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.

Annals of clinical and translational neurology·2025
Same author

A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.

Neurology·2025
Same journal

FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a primary cause of neurologic disability in young adults.
  • Interferon-beta, approved in 1993, was the first disease-modifying therapy for MS and is still widely used.
  • Clinical trials confirm its efficacy in reducing relapses and delaying disability progression in early, active MS.

Purpose of the Study:

  • To review the established efficacy and ongoing research into interferon-beta for multiple sclerosis.
  • To discuss the proposed anti-inflammatory mechanisms of interferon-beta.
  • To highlight areas of uncertainty regarding patient response and optimal administration.

Main Methods:

  • Review of large-scale clinical trials and immunologic research.
  • Analysis of magnetic resonance imaging (MRI) data showing reduced active lesions.
  • Exploration of factors influencing individual patient responsiveness.

Main Results:

  • Interferon-beta effectively reduces relapses and delays disability progression in MS.
  • Evidence suggests anti-inflammatory properties, supported by MRI and basic research.
  • Therapeutic effect magnitude appears consistent across different interferon-beta products.

Conclusions:

  • Interferon-beta remains a cornerstone therapy for multiple sclerosis.
  • Understanding its mechanism of action and optimizing treatment are ongoing research areas.
  • Further investigation is needed into optimal dosing, route, and frequency for individual MS patients.